Letter | Published:

Group 2 innate lymphoid cells promote beiging of white adipose tissue and limit obesity

Nature volume 519, pages 242246 (12 March 2015) | Download Citation

Abstract

Obesity is an increasingly prevalent disease regulated by genetic and environmental factors. Emerging studies indicate that immune cells, including monocytes, granulocytes and lymphocytes, regulate metabolic homeostasis and are dysregulated in obesity1,2. Group 2 innate lymphoid cells (ILC2s) can regulate adaptive immunity3,4 and eosinophil and alternatively activated macrophage responses5, and were recently identified in murine white adipose tissue (WAT)5 where they may act to limit the development of obesity6. However, ILC2s have not been identified in human adipose tissue, and the mechanisms by which ILC2s regulate metabolic homeostasis remain unknown. Here we identify ILC2s in human WAT and demonstrate that decreased ILC2 responses in WAT are a conserved characteristic of obesity in humans and mice. Interleukin (IL)-33 was found to be critical for the maintenance of ILC2s in WAT and in limiting adiposity in mice by increasing caloric expenditure. This was associated with recruitment of uncoupling protein 1 (UCP1)+ beige adipocytes in WAT, a process known as beiging or browning that regulates caloric expenditure7,8,9. IL-33-induced beiging was dependent on ILC2s, and IL-33 treatment or transfer of IL-33-elicited ILC2s was sufficient to drive beiging independently of the adaptive immune system, eosinophils or IL-4 receptor signalling. We found that ILC2s produce methionine-enkephalin peptides that can act directly on adipocytes to upregulate Ucp1 expression in vitro and that promote beiging in vivo. Collectively, these studies indicate that, in addition to responding to infection or tissue damage, ILC2s can regulate adipose function and metabolic homeostasis in part via production of enkephalin peptides that elicit beiging.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    & Inflammatory links between obesity and metabolic disease. J. Clin. Invest. 121, 2111–2117 (2011)

  2. 2.

    & The cellular and signaling networks linking the immune system and metabolism in disease. Nature Med. 18, 363–374 (2012)

  3. 3.

    et al. Innate production of TH2 cytokines by adipose tissue-associated c-Kit+Sca-1+ lymphoid cells. Nature 463, 540–544 (2010)

  4. 4.

    et al. Group 2 innate lymphoid cells are critical for the initiation of adaptive T helper 2 cell-mediated allergic lung inflammation. Immunity 40, 425–435 (2014)

  5. 5.

    et al. Innate lymphoid type 2 cells sustain visceral adipose tissue eosinophils and alternatively activated macrophages. J. Exp. Med. 210, 535–549 (2013)

  6. 6.

    , , & Cutting edge: IL-25 elicits innate lymphoid type 2 and type II NKT cells that regulate obesity in mice. J. Immunol. 191, 5349–5353 (2013)

  7. 7.

    & Brown and beige fat: development, function and therapeutic potential. Nature Med. 19, 1252–1263 (2013)

  8. 8.

    et al. UCP1 in brite/beige adipose tissue mitochondria is functionally thermogenic. Cell Rep. 5, 1196–1203 (2013)

  9. 9.

    et al. Ablation of PRDM16 and beige adipose causes metabolic dysfunction and a subcutaneous to visceral fat switch. Cell 156, 304–316 (2014)

  10. 10.

    et al. Systemically dispersed innate IL-13-expressing cells in type 2 immunity. Proc. Natl Acad. Sci. USA 107, 11489–11494 (2010)

  11. 11.

    et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature 464, 1367–1370 (2010)

  12. 12.

    et al. Interleukin-33 induces protective effects in adipose tissue inflammation during obesity in mice. Circ. Res. 107, 650–658 (2010)

  13. 13.

    et al. Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161. Nature Immunol. 12, 1055–1062 (2011)

  14. 14.

    et al. Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus. Nature Immunol. 12, 1045–1054 (2011)

  15. 15.

    et al. T cell factor 1 is required for group 2 innate lymphoid cell generation. Immunity 38, 694–704 (2013)

  16. 16.

    et al. IL-33 reduces the development of atherosclerosis. J. Exp. Med. 205, 339–346 (2008)

  17. 17.

    et al. Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human. Cell 150, 366–376 (2012)

  18. 18.

    & What we talk about when we talk about fat. Cell 156, 20–44 (2014)

  19. 19.

    , , & UCP1 ablation induces obesity and abolishes diet-induced thermogenesis in mice exempt from thermal stress by living at thermoneutrality. Cell Metab. 9, 203–209 (2009)

  20. 20.

    et al. Ephedrine activates brown adipose tissue in lean but not obese humans. Diabetologia 56, 147–155 (2013)

  21. 21.

    et al. High incidence of metabolically active brown adipose tissue in healthy adult humans: effects of cold exposure and adiposity. Diabetes 58, 1526–1531 (2009)

  22. 22.

    et al. Eosinophils and type 2 cytokine signaling in macrophages orchestrate development of functional beige fat. Cell 157, 1292–1308 (2014)

  23. 23.

    et al. Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis. Science 332, 243–247 (2011)

  24. 24.

    et al. Reducing RIP140 expression in macrophage alters ATM infiltration, facilitates white adipose tissue browning, and prevents high-fat diet-induced insulin resistance. Diabetes 63, 4021–4031 (2014)

  25. 25.

    et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nature Med. 15, 930–939 (2009)

  26. 26.

    Genomics, type 2 diabetes, and obesity. N. Engl. J. Med. 363, 2339–2350 (2010)

  27. 27.

    , & The genetic contribution to non-syndromic human obesity. Nature Rev. Genet. 10, 431–442 (2009)

  28. 28.

    , , & The multifaceted proprotein convertases: their unique, redundant, complementary, and opposite functions. J. Biol. Chem. 288, 21473–21481 (2013)

  29. 29.

    , & Obesity, hyperphagia and increased metabolic efficiency in Pc1 mutant mice. Hum. Mol. Genet. 15, 1884–1893 (2006)

  30. 30.

    et al. Human BAT possesses molecular signatures that resemble beige/brite cells. PLoS ONE 7, e49452 (2012)

  31. 31.

    & in Epidemiology: Principles and Practical Guidelines (eds & ) pp. 137–155 (Springer, 2013)

  32. 32.

    , , , & Opioid growth factor suppresses expression of experimental autoimmune encephalomyelitis. Brain Res. 1310, 154–161 (2010)

  33. 33.

    et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412–419 (1985)

  34. 34.

    et al. Prdm16 determines the thermogenic program of subcutaneous white adipose tissue in mice. J. Clin. Invest. 121, 96–105 (2011)

Download references

Acknowledgements

The authors wish to thank members of the Artis laboratory for the critical reading of this manuscript. Research in the Artis laboratory is supported by the National Institutes of Health (AI061570, AI074878, AI095466, AI095608, AI102942, and AI097333 to D.A.), the Burroughs Wellcome Fund Investigator in Pathogenesis of Infectious Disease Award (D.A.) and Crohn’s & Colitis Foundation of America (D.A.). Additional funding was provided by NIH F30-AI112023 (J.R.B.), T32-AI060516 (J.R.B.), T32-AI007532 (L.A.M.), KL2-RR024132 (B.S.K.), DP5OD012116 (G.F.S.), P01AI06697 (D.L.F.), F31AG047003 (J.J.T.) and DP2OD007288 (P.S.) and by the Searle Scholars Award (P.S.). We thank M. A. Lazar for scientific and technical advice, D. E. Smith for providing Il33−/− mice, A. Goldrath for providing Id2−/− chimaeras, and A. Bhandoola for providing Tcf7−/− mice. We also thank the Mouse Phenotyping, Physiology & Metabolism Core at the Diabetes Research Center (DRC) of the Institute for Diabetes, Obesity & Metabolism (IDOM) as well as the Penn Diabetes Endocrine Research Center Grant (P30DK19525). In addition, we thank the Matthew J. Ryan Veterinary Hospital Pathology Laboratory, the Penn Microarray Facility, and the Mucosal Immunology Studies Team (MIST) of the NIH NIAID for shared expertise and resources. The authors would also like to thank the Abramson Cancer Center Flow Cytometry and Cell Sorting Resource Laboratory for technical advice and support. The ACC Flow Cytometry and Cell Sorting Shared Resource is partially supported by NCI Comprehensive Cancer Center Support Grant (no. 2-P30 CA016520). This work was supported by the NIH/NIDDK P30 Center for Molecular Studies in Digestive and Liver Diseases (P30-DK050306), its pilot grant program and scientific core facilities (Molecular Pathology and Imaging, Molecular Biology, Cell Culture and Mouse), as well as the Joint CHOP-Penn Center in Digestive, Liver and Pancreatic Medicine and its pilot grant program. In addition, we would like to acknowledge and thank the New York Organ Donor Network, the Cooperative Human Tissue Network-Eastern Division and especially the donors and their families. We apologize to colleagues whose work we were unable to quote owing to space constraints.

Author information

Author notes

    • Brian S. Kim
    •  & Steven A. Saenz

    Present addresses: Division of Dermatology, Department of Medicine, Washington University School of Medicine, St Louis, Missouri 63110, USA (B.S.K.); Immunology Research, Biogen Idec, Inc., Cambridge, Massachusetts 02142, USA (S.A.S.).

Affiliations

  1. Jill Roberts Institute for Research in IBD, Joan and Sanford I. Weill Department of Medicine, Department of Microbiology and Immunology, Weill Cornell Medical College, Cornell University, New York, New York 10021, USA

    • Jonathan R. Brestoff
    • , Laurel A. Monticelli
    • , Gregory F. Sonnenberg
    •  & David Artis
  2. Department of Microbiology and Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA

    • Jonathan R. Brestoff
    • , Brian S. Kim
    • , Steven A. Saenz
    • , Laurel A. Monticelli
    •  & David Artis
  3. Institute for Diabetes, Obesity and Metabolism, Department of Cell and Developmental Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA

    • Rachel R. Stine
    •  & Patrick Seale
  4. Columbia Center for Translational Immunology, Columbia University Medical Center, New York, New York 10032, USA

    • Joseph J. Thome
    •  & Donna L. Farber
  5. Department of Microbiology and Immunology, Columbia University Medical Center, New York, New York 10032, USA

    • Joseph J. Thome
    •  & Donna L. Farber
  6. Department of Surgery, Columbia University Medical Center, New York, New York 10032, USA

    • Donna L. Farber
  7. Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, California 91766, USA

    • Kabirullah Lutfy

Authors

  1. Search for Jonathan R. Brestoff in:

  2. Search for Brian S. Kim in:

  3. Search for Steven A. Saenz in:

  4. Search for Rachel R. Stine in:

  5. Search for Laurel A. Monticelli in:

  6. Search for Gregory F. Sonnenberg in:

  7. Search for Joseph J. Thome in:

  8. Search for Donna L. Farber in:

  9. Search for Kabirullah Lutfy in:

  10. Search for Patrick Seale in:

  11. Search for David Artis in:

Contributions

J.R.B., B.S.K., S.A.S., R.R.S., L.A.M., G.F.S., K.L., P.S. and D.A. designed and performed the research and/or provided advice and technical expertise. J.J.T. and D.L.F. provided human tissues. J.R.B. and D.A. analysed the data and wrote the manuscript.

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to David Artis.

Extended data

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/nature14115

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.